secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001493152-26-000896
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bone Biologics highlights 2025 milestones including $5M offering, 24-month shelf life, Nasdaq compliance
--------------------------------------------------------------------------------

- Extended validated shelf life of rhNELL-1 protein product candidate to 24 months (prior 12/18 months).
- Completed $5M registered public offering in Q2 2025 to fund clinical development and IP initiatives.
- Regained Nasdaq minimum bid price compliance in June 2025, maintaining public market access.
- Filed U.S. patent application for recombinant human NELL-1 bone regeneration technology.
- Expects to complete patient enrollment in NB1 first-in-human clinical trial during 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315226000896/0001493152-26-000896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315226000896/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-000896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer